skip to main content

MDM2 Liposarcoma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardSarcomaMDM2 LiposarcomaSCE Medical Oncology

An adult with metastatic NTRK-fusion-positive salivary carcinoma and no satisfactory standard option is being considered for entrectinib. A colleague cites the old Cancer Drugs Fund recommendation TA644. Which statement reflects the current NICE position in England?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — TA1118 replaced TA644 and NICE made no recommendation because a complete evidence submission was not provided; existing treated patients may continue

Explanation lettering: D = shown as A · A = shown as B · B = shown as C · C = shown as D

C is correct. A ignores the 2026 replacement appraisal; B invents a fusion-specific funding rule; D invents a sequencing recommendation; E contradicts the tumour-agnostic indication. Lack of a NICE recommendation is not the same as evidence of biological ineffectiveness.

Reference: NICE TA1118 entrectinib for NTRK fusion-positive tumours: terminated appraisal (Published 7 January 2026): https://www.nice.org.uk/guidance/ta1118/chapter/Advice